Novel target for anti-cancer and immune-enhancing
AssigneeGenome and Company
InventorsBu-Nam JEON, Yun Yeon Kim, Suro Lee, Youn Kyung Houh, Joo-Yeon Chung, Areum Jeong, Mi Young Cha
Life of this patent
Estimating the term…
Abstract
The present disclosure provides a pharmaceutical composition for treating or preventing cancer, comprising inhibitors of KIRREL3, CNTN4 and/or CD351. In addition, the present disclosure provides a pharmaceutical composition for immune-enhancing, comprising inhibitors of KIRREL3, CNTN4 and/or CD351. Furthermore, the present disclosure provides a method of screening of anti-cancer agent using KIRREL3, CNTN4 and/or CD351, and a method of providing information necessary for analysis of cancer prognosis using KIRREL3, CNTN4 and/or CD351.
Claims16
A method of screening an anti-cancer agent comprising:
- (a) treating a cancer cell with a candidate anti-cancer agent;
- and
- (b) measuring expression or activity of CNTN4 in the cancer cell.
A method of screening an anti-cancer agent comprising:
- (a) treating a cancer cell with a candidate anti-cancer agent;
- and
- (b) measuring a binding of amyloid precursor protein (APP) to CNTN4.
A method of screening an anti-cancer agent comprising:
- (a) treating a cancer cell with a candidate anti-cancer agent;
- and
- (b) determining the candidate anti-cancer agent to be an anti-cancer agent if a group treated with the candidate anti-cancer agent shows a significantly increased level of cell death within CNTN4 expressing cells when treated with the candidate anti-cancer agent compared to a group not treated with the candidate anti-cancer agent.
A method of providing information necessary for analysis of cancer prognosis using CNTN4.
Dependencies are inferred from the claim text.